Premium
Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation
Author(s) -
Idilman Ramazan,
Üstün Celalettin,
Karayalçın Selim,
Aktemel Aslihan,
Turkyilmaz Ahmet R,
Özcan Muhit,
Arslan Onder,
Bozdayi A Mithat,
Van Thiel David H,
Akan Hamdi
Publication year - 2003
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1034/j.1399-0012.2003.00070.x
Subject(s) - medicine , seroconversion , hepatitis b virus , transplantation , immunology , vaccination , hepatitis b , antibody , immunization , virology , virus
Background: The aim of this study was to determine the role of hepatitis B virus (HBV) vaccination as defined by the seroconversion to hepatitis B surface antibody (anti‐HBs) positivity in peripheral blood stem cell transplants. Methods: A total of 65 recipients and their donors were enrolled in this study. Recipients were divided into four distinct groups. Group 1 consisted of individuals who were vaccinated, group 2 consisted of individuals who were naturally immunized, group 3 consisted of individuals who were HBs‐Ag positive, and group 4 consisted of individuals who were HBV naïve and not vaccinated. Results: Eighty‐eight percent of the HBV‐vaccinated recipients (14 of 16), who had vaccinated‐donors, seroconverted to anti‐HBs positivity. Eighty‐three percent of HBV‐naïve recipients (five of six), who received stem cells from HBV‐immune donors, seroconverted to anti‐HBs positivity. Two of the four HBs‐Ag positive recipients with HBV‐immune donors seroconverted to anti‐HBs positivity after transplantation. Fifty‐seven percent of previously vaccinated‐recipients (eight of 14) lost detectable anti‐HBs antibody following transplantation. Finally, 31% of HBV‐naïve recipients with HBV‐naïve donors acquired a de novo HBV infection. Conclusions: (i) Hepatitis B virus immunization of recipients of allogeneic hematopoietic cell transplantation results in an effective antibody response. (ii) The HBV‐immune status of the donor plays an important role in post‐transplantation HBs‐Ab on seroconversion. (iii) Systematic re‐immunization of recipients will be necessary to maintain HBV immunity in long‐term serving recipients.